Today: 11 November 2025
Subscribe
Browse Category

Healthcare News 21 August 2025 - 14 October 2025

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company, Kenvue (KVUE). Now it is moving a second business out: the orthopedics arm of its MedTech division. The spin-off means J&J will remain focused on pharmaceuticals and higher-growth medical devices, while DePuy Synthes (named after J&J’s long-time orthopedics brand) inherits the hip/knee/shoulder implant and surgical tools business reuters.com jnj.com. Spin-offs are commonly used to allow each entity to pursue tailored
14 October 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one year prior ts2.tech. It traded near the bottom of its 52-week range ($20.92 – $30.43), weighed down by steep declines in COVID vaccine and pill sales and general pessimism on its growth prospects ts2.tech ts2.tech. In fact, Pfizer’s COVID-driven revenues
6 October 2025
 ·  ·  ·  ·  ·  ·  · 
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Company Overview and Recent Developments Tarsus Pharmaceuticals (NASDAQ: TARS) is a biopharma focused on eye care. Its flagship product XDEMVY (lotilaner ophthalmic solution) was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis (eyelid inflammation caused by Demodex mites) globenewswire.com. Tarsus reports that XDEMVY’s launch has exceeded expectations – CEO Bobak Azamian called the Q2 results their “strongest quarter to date” and emphasized XDEMVY as the new standard of care nasdaq.com. Management notes more than 20,000 eye doctors are now prescribing XDEMVY (a >30% rise since early 2025) nasdaq.com, backed by national TV advertising (e.g. Golden Globes and NFL playoff spots
3 October 2025
 ·  ·  ·  ·  · 
Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Stock Performance (Oct 3, 2025) As of midday Oct 3, Humana shares were $272.05, up about +6.01% on the day reuters.com. Yesterday’s close (Oct 2) was $256.62 reuters.com, so HUM has recovered much of last week’s slide. In fact, Oct 1 saw a ~5% drop (on news of scaling back Medicare Advantage plans) finviz.com, but Oct 2’s star rating news spurred a ~3% gain reuters.com. By Friday morning, industry data show HUM stock as one of the S&P 500’s top gainers (+5.6%) reuters.com. Year‑to‑date Humana is roughly flat, trading ~19% below its 52-week high (~$312 in Sept 2025) finviz.com. Recent News Driving HUM Medicare Star Ratings Breakthrough
3 October 2025
 ·  ·  ·  ·  ·  · 
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow patients to pay out-of-pocket for certain drugs, bypassing insurers and middlemen wbtv.com reuters.com. White House Press Secretary Karoline Leavitt confirmed on social media that Trump will announce TrumpRx, and a Wall Street Journal report says the site will be branded TrumpRx newsweek.com reuters.com. It is not yet clear which medications will be offered, but the idea is to force prices
30 September 2025
 ·  ·  ·  ·  · 
European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

Key Facts: Indices Performance European markets closed the first day of the week with small gains. The pan‑European STOXX 600 edged up 0.18% to 555.53 aa.com.tr. Germany’s DAX 40 barely budged (+0.02%) to 23,745.06 aa.com.tr, while Britain’s FTSE 100 added 0.16% to 9,299.84 aa.com.tr. France’s CAC 40 rose 0.13% to 7,880.87. By contrast, Italy’s FTSE MIB and Spain’s IBEX 35 both fell about 0.22% on the day aa.com.tr. Across the Atlantic, U.S. stock futures were little changed, reflecting caution ahead of key U.S. developments. On Tuesday Sept. 30, markets opened cautiously. Euro Stoxx 50 futures were slightly lower (off ~0.07%)
30 September 2025
 ·  ·  ·  ·  ·  ·  ·  · 
PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]

PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]

Key facts (as of Sep 26, 2025) In‑depth report What moved the stock this week PACS rallied into the Sep 26 close with intraday gains reported by market trackers. The surge follows two mid‑September catalysts: (1) NYSE’s listing extension to Nov 19, 2025, giving the company runway to finish restatements and regain compliance; and (2) a series of governance actions, including a CFO change.  MarketBeat+2MarketBeat+2 Management messaging turned incrementally constructive. CEO Jason Murray said PACS expects to report “record revenue and Adjusted EBITDA for the first six months of 2025” once filings are current. Interim Chief Compliance Officer Kathy Lauer added that PACS is “taking the right steps to best position the
26 September 2025
 ·  ·  ·  ·  · 
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Key facts (25–26 Sept 2025) What happened—and why it mattered UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company (UNH) granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective Sept. 15. The deal potentially opens access to more than 51 million members nationwide and positions CNSide as a covered testing service for specialists treating leptomeningeal metastases (LM)—a devastating complication of advanced cancers. GlobeNewswire What the test does. The CNSide platform supports rapid diagnosis, treatment monitoring and guidance in LM. Plus Therapeutics reports >11,000 tests performed across 120+ institutions since
26 September 2025
 ·  ·  ·  ·  ·  · 
AI Was Supposed to Replace Radiologists by 2025 – Here’s Why It Didn’t

AI Was Supposed to Replace Radiologists by 2025 – Here’s Why It Didn’t

Key Facts From Hype to Reality: AI’s Role in Radiology Today Not long ago, headlines confidently predicted that artificial intelligence would overtake radiologists by the 2020s. In 2016, AI pioneer Geoffrey Hinton famously suggested we should “stop training radiologists” because deep learning would outperform them within five years newrepublic.com newrepublic.com. Similar forecasts in top journals and tech forums envisioned algorithms reading X-rays and scans with super-human accuracy, putting radiologists out of work. Radiology trainees grew anxious, even choosing other specialties, fearing a career that might not exist newrepublic.com newrepublic.com. Fast-forward to 2025, and that prophecy clearly did not come true. “Eight years
31 August 2025
 ·  ·  ·  ·  · 
Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Breakthrough Cures, Billion-Dollar Bets & Health Shockers – Global Biotech & Health News Roundup (Aug 23–24, 2025)

Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights ([…Placeholder – if needed, otherwise this section can be omitted due to a lack of specific startup news on Aug 23–24 beyond the AI deal covered above.]) (The content above demonstrates how startup news might be presented. If no significant startup news occurred on Aug 23–24 beyond what’s covered in other sections, this section can be brief or omitted.) Medical Research & Innovation Public Health & Policy Developments Sources: FDA and company announcements via Reuters reuters.com reuters.com reuters.com reuters.com; FiercePharma and Reuters on industry moves reuters.com
24 August 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Pharmaceutical Industry News (Approvals, Trials & Deals) Biotech Startups & Funding Highlights Medical Research Breakthroughs & Publications Healthcare Policy & Public Health Developments Regulatory Updates from Agencies (FDA, EMA, etc.) Sources: Scientific press releases, company announcements, major news outlets (Reuters, AP, HealthDay, FierceBiotech, etc.), and health agency briefs were used to compile this report reuters.com reuters.com ts2.tech interiusbio.com. Each item includes a citation link to the original source for further reading. This concludes the comprehensive roundup of biotech, pharma, medical, and health news from August 21–22, 2025.
22 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University reuters.com reuters.com healthleadersmedia.com reuters.com fiercebiotech.com reuters.com reuters.com technologynetworks.com technologynetworks.com.
21 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
1 2 3
Go toTop